Acute myeloid leukaemia (AML) is a common type of blood cancer in childhood and can be diagnosed within a few months of life. New research shows that its origins can be traced back to before birth.
Blood cancer cells can remain in the blood of AML patients, even after chemotherapy seemed successful. Testing for these residuals before blood cell donation is a vital precaution, a new study finds.
Certain genetic features are crucial for treatment decisions for AML leukaemia. A team from Münster shows how an AI-based method can predict these features from images of bone marrow smears.
Using data from more than 400,000 individuals, researchers have created a platform for predicting the risk of developing blood cancers such as acute myeloid leukaemia over a 10-15-year period.
Some leukemias evade treatment by changing their appearance and identity through changing the read-out of their DNA, a new study has found.
The oncogene EVI1 causes an aggressive type of leukemia, but its exact function has been a mystery. A research team now showed that EVI1's cancer causing effect relies on activating a single gene — the stem cell transcription factor ERG.
By analysing secondary acute myeloid leukaemias, researchers at the Institute for Research in Biomedicine (IRB) Barcelona have detected mutations caused by platinum-based chemotherapies in cells that were healthy at the time of treatment. Treatment with chemotherapies influences the development of blood cells, favouring clonal hematopoiesis from cells with pre-existing mutations. The study has…
New research has uncovered a surprising role for so-called “jumping” genes that are a source of genetic mutations responsible for a number of human diseases. In the new study from Children’s Medical Center Research Institute at UT Southwestern (CRI), scientists made the unexpected discovery that these DNA sequences, also known as transposons, can protect against certain blood cancers. These…
In their quest to find new and better methods to make cancer cells more susceptible to treatment, Karin Lindkvist and her research group at Lund University in Sweden are looking into the world of molecules, using the X-rays at the MAX IV laboratory. The researchers believe that limiting the cells' access to sugar will make cancer cells more sensitive to treatment. Many of the cancer treatments…
For the first time, researchers from Helmholtz Zentrum München and the University Hospital of LMU Munich show that deep learning algorithms perform similar to human experts when classifying blood samples from patients suffering from acute myeloid leukemia (AML). Their proof of concept study paves the way for an automated, standardized and on-hand sample analysis in the near future. The paper was…
Oxford Gene Technology (OGT), A Sysmex Group Company, has celebrated the opening of its new facility in Cambridge, UK. The opening ceremony, which took place at the company’s new premises on the prestigious Cambridge Science Park, was attended by the Department for International Trade (DIT) and local media as well as top-level representatives from OGT and its parent company, Sysmex Corporation.…
Stem cells are surrounded and protected by the stem-cell niche – the microenvironment – of the tissue in which they are found. Researchers at Karolinska Institutet have mapped the stem-cell niche in the bone marrow of mice and studied how it is influenced by developing leukemia. Their results, which are published in the journal Cell, show that the bone-marrow microenvironment is more complex…
New findings about a fatal form of blood cancer could aid the development of new drugs with significantly less harmful side effects than existing chemotherapy. The discovery could lead to novel treatments that efficiently eliminate blood cancer cells in acute myeloid leukaemia (AML), without harming healthy blood cells. Researchers have discovered how a protein in the body plays a key role in AML…
For the first time, a team of international researchers have mapped the family trees of cancer cells in acute myeloid leukaemia (AML) to understand how this blood cancer responds to a new drug, enasidenib. The work also explains what happens when a patient stops responding to the treatment, providing important clues about how to combine enasidenib with other anti-cancer drugs to produce…
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Last January Dr Maurizio Pupi became the International Business Manager of Vanguard Healthcare – the UK supplier of mobile healthcare facilities – which intends to spread its already very established and necessary services beyond the United Kingdom.